Quick Answer
Adicet Bio, Inc. reported Cash And Cash Equivalents At Carrying Value of $38.92 million for the year ending 2025.
- Adicet Bio, Inc. showed a decrease of -31.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Adicet Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $3.31 million | Q3 2017: $3.97 million | Q4 2017: $53.35 million | Q1 2018: $135.71 million | Q2 2018: $51.35 million | Q3 2018: $22.86 million | Q1 2019: $7.18 million | Q2 2019: $21.37 million | Q3 2019: $23.00 million | Q1 2020: $6.74 million | Q2 2020: $18.26 million | Q3 2020: $84.96 million | Q1 2021: $221.67 million | Q2 2021: $208.73 million | Q3 2021: $192.23 million | Q1 2022: $277.88 million | Q2 2022: $260.64 million | Q3 2022: $282.68 million | Q1 2023: $231.64 million | Q2 2023: $205.46 million | Q3 2023: $183.26 million | Q1 2024: $159.71 million | Q2 2024: $224.07 million | Q3 2024: $105.48 million | Q1 2025: $28.13 million | Q2 2025: $34.72 million | Q3 2025: $29.10 million.
- Historical annual values: Fiscal year 2025: $38.92 million | Fiscal year 2024: $56.50 million | Fiscal year 2023: $159.71 million | Fiscal year 2022: $257.66 million | Fiscal year 2021: $277.54 million | Fiscal year 2020: $84.33 million | Fiscal year 2019: $10.61 million | Fiscal year 2018: $9.48 million | Fiscal year 2017: $53.35 million | Fiscal year 2016: $0.00 | Fiscal year 2016: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: